Drugs / VRC-HIVMAB075-00-AB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02840474 | Apr 2017 → Jan 2020 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03015181 | Feb 2017 → Jul 2018 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-HIVMAB075-00-AB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02840474 ↗ |
| Action | Inhibit | “VRC07-523LS administration significantly decreased VL in 8 out of 9 participants, with an average decline of 1.7 ± 0.8 log10 copies/mL within 14 days after administration.” PMID 39989458 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB075-00-AB (VRC07-523LS) are human monoclonal antibodies (MAbs) targeted to the CD4+ binding site of HIV-1.” NCT02840474 ↗ |
| Route | Intravenous | “VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0” NCT02840474 ↗ |